AndroGel maker AbbVie, won the verdict in the third bellwether case as the jury found that the testosterone replacement therapy maker was not liable for the plaintiff’s pulmonary embolism condition. The case was a part of lawsuits centralized under MDL 2545 (In re: Testosterone Replacement Therapy Products Liability Litigation), in the U.S. District Court for the Northern District of Illinois before U.S. District Judge Matthew Kennelly. The lawsuits allege that the defendants named in this MDL fabricated a condition called “Low T,” which was merely the natural effects of aging resulting in thousands of men exposed to the risk of cardiovascular side effects.
More than 6,000 lawsuits are a part of the Testosterone Replacement Therapy Products Liability Litigation, with more than 4,500 cases filed against AbbVie. However, AbbVie has said that its marketing of AndroGel adhered strictly to uses approved by the FDA and that it was in full compliance with applicable standards.